This report examines the clinical utility of PTEN genetic testing of patients at risk for, or diagnosed with, PTEN hamartoma tumor syndrome (PHTS) based upon clinical symptoms, with or without a family history suggestive of PHTS. The goal of this report is to assess how genetic testing of patients meeting this criteria changes patient management, informs treatment selection and/or prognosis, and impacts at-risk family members.
If you have a Hayes login, click here to view the full report on the Knowledge Center.